Insys Therapeutics, Inc. shares had a trading volume of 0 on Monday. Shares saw a steep decrease in trading volume of 100.00% under the normal average daily volume.
Short traders are feeling a little more bearish on Insys Therapeutics, Inc. of late if you pay attention to the uptick in short interest. The firm realized a rise in short interest of 5.98% as of the latest report on October 13, 2017. Short interest increased from 10,970,265 to 11,626,213 over that period. With short interest at 11,626,213 and short average daily volume at 1,049,499, days to cover is 11.0 and the percentage of shorted shares is 0.16% as of October 13.
Here are a few substantial investment firms who have updated their positions. Meeder Asset Management Inc grew its investment by buying 221 shares an increase of 45.7%. Meeder Asset Management Inc owns 705 shares worth $6,000. The value of the position overall is down by 0.0%. Shell Asset Management CO expanded its stake by buying 60,904 shares an increase of 178.0% as of 09/30/2017. Shell Asset Management CO now controls 95,127 shares valued at $845,000. The total value of its holdings increased 95.2%.
As of quarter end TCI Wealth Advisors, Inc. had disposed of a total of 2,000 shares trimming its position 17.4%. The value in dollars went from $146,000 to $85,000 a change of $61,000 quarter to quarter. Whittier Trust CO augmented its holdings by buying 51 shares an increase of 85.0% from 06/30/2017 to 09/30/2017. Whittier Trust CO currently owns 111 shares with a value of $1,000. The total value of its holdings decreased 0.0%.
The company is down by 10.28% since yesterday’s close of $5.15. Shares are trading at $5.15 which is quite a bit lower than $8.23, the 50 day moving average and which is well below the 200 day moving average of $10.57. The 50 day moving average went down $-3.08 or -37.40% and the 200 day average was down $-5.42.
As of the last earnings report the EPS was $-0.22 and is estimated to be $-0.33 for the current year with 72,696,000 shares now outstanding. Next quarter’s EPS is expected be $-0.12 and the next full year EPS is anticipated to be $-0.19.
Insys Therapeutics, Inc., launched on June 15, 1990, is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. Subsys is the Business’s marketed product. Subsys is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and is a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States..